S&P 500   2,677.88 (+0.53%)
DOW   22,816.90 (+0.60%)
QQQ   197.14 (+0.34%)
AAPL   260.70 (-0.67%)
FB   168.48 (+1.77%)
MSFT   164.73 (-0.33%)
GOOGL   1,185.05 (+0.16%)
AMZN   2,011.46 (+0.69%)
CGC   14.40 (+0.42%)
NVDA   259.53 (-3.30%)
BABA   197.49 (+0.53%)
MU   46.71 (+0.73%)
GE   7.06 (-2.89%)
TSLA   544.43 (+5.46%)
AMD   47.73 (+0.42%)
T   30.18 (+2.51%)
ACB   0.80 (+0.00%)
F   4.71 (+2.84%)
NFLX   372.22 (-2.04%)
BAC   22.19 (+3.74%)
GILD   74.50 (-4.00%)
DIS   100.59 (+1.01%)
S&P 500   2,677.88 (+0.53%)
DOW   22,816.90 (+0.60%)
QQQ   197.14 (+0.34%)
AAPL   260.70 (-0.67%)
FB   168.48 (+1.77%)
MSFT   164.73 (-0.33%)
GOOGL   1,185.05 (+0.16%)
AMZN   2,011.46 (+0.69%)
CGC   14.40 (+0.42%)
NVDA   259.53 (-3.30%)
BABA   197.49 (+0.53%)
MU   46.71 (+0.73%)
GE   7.06 (-2.89%)
TSLA   544.43 (+5.46%)
AMD   47.73 (+0.42%)
T   30.18 (+2.51%)
ACB   0.80 (+0.00%)
F   4.71 (+2.84%)
NFLX   372.22 (-2.04%)
BAC   22.19 (+3.74%)
GILD   74.50 (-4.00%)
DIS   100.59 (+1.01%)
S&P 500   2,677.88 (+0.53%)
DOW   22,816.90 (+0.60%)
QQQ   197.14 (+0.34%)
AAPL   260.70 (-0.67%)
FB   168.48 (+1.77%)
MSFT   164.73 (-0.33%)
GOOGL   1,185.05 (+0.16%)
AMZN   2,011.46 (+0.69%)
CGC   14.40 (+0.42%)
NVDA   259.53 (-3.30%)
BABA   197.49 (+0.53%)
MU   46.71 (+0.73%)
GE   7.06 (-2.89%)
TSLA   544.43 (+5.46%)
AMD   47.73 (+0.42%)
T   30.18 (+2.51%)
ACB   0.80 (+0.00%)
F   4.71 (+2.84%)
NFLX   372.22 (-2.04%)
BAC   22.19 (+3.74%)
GILD   74.50 (-4.00%)
DIS   100.59 (+1.01%)
S&P 500   2,677.88 (+0.53%)
DOW   22,816.90 (+0.60%)
QQQ   197.14 (+0.34%)
AAPL   260.70 (-0.67%)
FB   168.48 (+1.77%)
MSFT   164.73 (-0.33%)
GOOGL   1,185.05 (+0.16%)
AMZN   2,011.46 (+0.69%)
CGC   14.40 (+0.42%)
NVDA   259.53 (-3.30%)
BABA   197.49 (+0.53%)
MU   46.71 (+0.73%)
GE   7.06 (-2.89%)
TSLA   544.43 (+5.46%)
AMD   47.73 (+0.42%)
T   30.18 (+2.51%)
ACB   0.80 (+0.00%)
F   4.71 (+2.84%)
NFLX   372.22 (-2.04%)
BAC   22.19 (+3.74%)
GILD   74.50 (-4.00%)
DIS   100.59 (+1.01%)
Log in

NASDAQ:TLGTTeligent Stock Price, Forecast & News

$0.32
+0.05 (+18.74 %)
(As of 04/7/2020 03:37 PM ET)
Add
Compare
Today's Range
$0.27
Now: $0.32
$0.33
50-Day Range
$0.22
MA: $0.36
$0.54
52-Week Range
$0.19
Now: $0.32
$1.13
Volume17,641 shs
Average Volume161,426 shs
Market Capitalization$17.26 million
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Teligent, Inc., a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. The company is also involved in contract manufacturing and development business, including the development, manufacturing, filling, and package of topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. Its topical semi-solid and liquid products are used in various applications that range from cosmetics and cosmeceuticals; and the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. Teligent, Inc. sells its products through national chain drug stores, drug wholesalers, distributors, and group purchasing organizations. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.
Read More
Teligent logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.93 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLGT
CUSIPN/A
Phone856-697-1441

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.86 million
Book Value$0.34 per share

Profitability

Net Income$-36,260,000.00

Miscellaneous

Employees189
Market Cap$17.26 million
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive TLGT News and Ratings via Email

Sign-up to receive the latest news and ratings for TLGT and its competitors with MarketBeat's FREE daily newsletter.


Teligent (NASDAQ:TLGT) Frequently Asked Questions

How has Teligent's stock been impacted by COVID-19 (Coronavirus)?

Teligent's stock was trading at $0.3250 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TLGT stock has decreased by 1.4% and is now trading at $0.3206. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Teligent?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teligent in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Teligent.

When is Teligent's next earnings date?

Teligent is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Teligent.

How were Teligent's earnings last quarter?

Teligent Inc (NASDAQ:TLGT) posted its quarterly earnings data on Monday, November, 4th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.01. The firm earned $18.47 million during the quarter, compared to analysts' expectations of $19.82 million. Teligent had a negative net margin of 51.29% and a negative return on equity of 232.25%. View Teligent's earnings history.

Has Teligent been receiving favorable news coverage?

News articles about TLGT stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Teligent earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutTeligent.

Who are some of Teligent's key competitors?

What other stocks do shareholders of Teligent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teligent investors own include Novavax (NVAX), ChemoCentryx (CCXI), Voyager Therapeutics (VYGR), General Electric (GE), Aquinox Pharmaceuticals (AQXP), Selecta Biosciences (SELB), AbbVie (ABBV), Exxon Mobil (XOM), Akorn (AKRX) and Biocept (BIOC).

Who are Teligent's key executives?

Teligent's management team includes the following people:
  • Mr. Jason Grenfell-Gardner M.B.A., M.B.A, Pres, CEO & Director (Age 44)
  • Mr. Stephen Richardson, Chief Scientific Officer (Age 53)
  • Mr. Martin Wilson, Gen. Counsel (Age 42)
  • Mr. Damian Finio, Corp. Sec. & CFO (Age 49)
  • Ms. Nadya Lawrence, Sr. VP of Technical Services (Age 50)

What is Teligent's stock symbol?

Teligent trades on the NASDAQ under the ticker symbol "TLGT."

How do I buy shares of Teligent?

Shares of TLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teligent's stock price today?

One share of TLGT stock can currently be purchased for approximately $0.32.

How big of a company is Teligent?

Teligent has a market capitalization of $17.26 million and generates $65.86 million in revenue each year. The company earns $-36,260,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. Teligent employs 189 workers across the globe. View additional information about Teligent.

What is Teligent's official website?

The official website for Teligent is http://www.teligent.com/.

How can I contact Teligent?

Teligent's mailing address is 105 LINCOLN AVENUE, BUENA NJ, 08310. The company can be reached via phone at 856-697-1441 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel